Philips (NYSE:PHG) said yesterday that it enrolled the first patient in a U.S. investigational device exemption trial for its Stellarex drug-coated balloon.
The 354-patient Illumenate Below-the-Knee study is designed to assess the device’s safety and effectiveness compared to percutaneous transluminal angioplasty in people with critical limb ischemia.
Get the full story at our sister site, Drug Delivery Business News.
The post Philips launches below-the-knee PAD trial for drug-coated balloon appeared first on MassDevice.